Phase 2Not yet recruitingGeroscience intervention
Urolithin A Supplementation During Pulmonary Rehabilitation in Patients With COPD (SUPRA-COPD)
The Supplementation With Urolithin A During Pulmonary Rehabilitation in COPD (SUPRA-COPD) Trial
- Sponsor
- Bryan A. Ross (Academic or other)
- Enrolment
- 198 planned
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Urolithin A; Placebo
- Ages
- adults, older adults
- Registry
- NCT07871357
Full record on ClinicalTrials.gov
From the registry
SUPRA-COPD is a multicenter triple-blind, parallel arm, placebo-controlled randomized controlled trial investigating the efficacy and safety of Urolithin A supplementation during pulmonary rehabilitation in patients with COPD. The goal of the SUPRA-COPD study is to investigate whether Urolithin A supplementation during pulmonary rehabilitation in patients with COPD improves exercise tolerance, along with several other clinically important outcomes, above and beyond pulmonary rehabilitation participation alone. Study participation will be approximately 14 weeks and involves in-person visits evaluating exercise tolerance before and after PR.
Primary outcomes
- Change in exercise endurance time (constant work rate exercise test, CWRET)
History
Primary completion expected
Expected to start
Registered